311 related articles for article (PubMed ID: 31749059)
1. Lasmiditan: First Approval.
Lamb YN
Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
[TBL] [Abstract][Full Text] [Related]
3. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
[TBL] [Abstract][Full Text] [Related]
4. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
6. Lasmiditan for the acute treatment of migraine.
Tepper D
Headache; 2020 Jun; 60(6):1225-1226. PubMed ID: 32474924
[No Abstract] [Full Text] [Related]
7. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
[TBL] [Abstract][Full Text] [Related]
9. Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.
Kudrow D; Krege JH; Hundemer HP; Berg PH; Khanna R; Ossipov MH; Pozo-Rosich P
Headache; 2020 Mar; 60(3):576-588. PubMed ID: 31943195
[TBL] [Abstract][Full Text] [Related]
10. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
11. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
[TBL] [Abstract][Full Text] [Related]
12. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
13. Lasmiditan Is a New Option for Acute Migraine Treatment.
Blakely KK; Stallworth K
Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
[TBL] [Abstract][Full Text] [Related]
14. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
15. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
16. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
[TBL] [Abstract][Full Text] [Related]
17. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
[TBL] [Abstract][Full Text] [Related]
18. Molecule of the month. Lasmiditan hydrochloride.
Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
[No Abstract] [Full Text] [Related]
19. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
[No Abstract] [Full Text] [Related]
20. The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.
Zhu H; Tang Y; Zhou T; Song J
Clin Neuropharmacol; 2020; 43(6):191-195. PubMed ID: 32969971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
